Compare YDDL & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | CYBN |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | Philippines | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 298.9M |
| IPO Year | 2025 | N/A |
| Metric | YDDL | CYBN |
|---|---|---|
| Price | $5.05 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $74.50 |
| AVG Volume (30 Days) | 81.6K | ★ 626.1K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 310.92 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $62,922,700.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.89 | ★ N/A |
| Revenue Growth | ★ 118.15 | N/A |
| 52 Week Low | $3.61 | $4.81 |
| 52 Week High | $8.89 | $10.73 |
| Indicator | YDDL | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.24 |
| Support Level | N/A | $5.70 |
| Resistance Level | N/A | $6.20 |
| Average True Range (ATR) | 0.00 | 0.36 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 0.00 | 75.00 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.